Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.

Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identif

Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).

Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.

Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder.

Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.

Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.

Abstract: Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of ototoxicity in response to receiving one or more platinum-coordinating compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of ototoxicity.

Abstract: Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of cardiotoxicity.

Abstract: A system and method for detecting a sampling clock offset of an analog-to-digital converter used to digitize an analog image signal. A method comprises buffering samples of an analog image signal, computing a value of an autocorrelation function using the buffered samples and a delayed version of the buffered samples, and repeating the computing a value for delays in a range of delays. The method also comprises computing a sampling frequency offset from the values of the autocorrelation function and changing a sampling frequency using the sampling frequency offset.

Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).

Abstract: A method and apparatus for an analog-to-digital video signal converter. The converter is controlled by a clock with controllable frequency and phase for sampling an analog signal. A circuit corrects the clock frequency using a period of a columnar frame differences as a function of columnar location. The sampling clock frequency is changed by an amount dependent on the period of the columnar differences. A second measure of the difference between successive frames is computed for a sequence of clock phases. The frequency of the clock is verified using a characteristic of the second measure. The characteristic can be the ratio of the maximum to the minimum of the second measure over selected clock phases. Other characteristics can be used such as a difference of a maximum and a minimum measure.

Abstract: Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of cardiotoxicity.

Abstract: The disclosure provides compositions and methods for the treatment of vascular, autoimmune, and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.

Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.

Abstract: A method and apparatus for an analog-to-digital video signal converter. The converter is controlled by a clock with controllable frequency and phase for sampling an analog signal. A circuit corrects the clock frequency using a period of a columnar frame differences as a function of columnar location. The sampling clock frequency is changed by an amount dependent on the period of the columnar differences. A second measure of the difference between successive frames is computed for a sequence of clock phases. The frequency of the clock is verified using a characteristic of the second measure. The characteristic can be the ratio of the maximum to the minimum of the second measure over selected clock phases. Other characteristics can be used such as a difference of a maximum and a minimum measure.

Abstract: A method and apparatus for an analog-to-digital video signal converter. The converter is controlled by a clock with controllable frequency and phase for sampling an analog signal. A circuit corrects the clock frequency using a period of a columnar frame differences as a function of columnar location. The sampling clock frequency is changed by an amount dependent on the period of the columnar differences. A second measure of the difference between successive frames is computed for a sequence of clock phases. The frequency of the clock is verified using a characteristic of the second measure. The characteristic can be the ratio of the maximum to the minimum of the second measure over selected clock phases. Other characteristics can be used such as a difference of a maximum and a minimum measure.

Abstract: A method and apparatus for an analog-to-digital video signal converter. The converter is controlled by a clock with controllable frequency and phase for sampling an analog signal. A measure of the difference between successive frames of the image is computed for a sequence of clock phases. The measure can be a count taken over pixels of the magnitude of the difference between a pixel in one frame and the corresponding pixel in a following frame exceeding a threshold value. The frequency of the clock is verified using a characteristic of the frame difference. The characteristic can be the ratio of the maximum measure to the minimum measure over the selected clock phases. Other characteristics can be used such as a difference of a maximum and a minimum measure.

Abstract: Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of ototoxicity in response to receiving one or more platinum-coordinating compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of ototoxicity.

Abstract: A system and method for detecting a sampling clock offset of an analog-to-digital converter used to digitize an analog image signal. A method comprises buffering samples of an analog image signal, computing a value of an autocorrelation function using the buffered samples and a delayed version of the buffered samples, and repeating the computing a value for delays in a range of delays. The method also comprises computing a sampling frequency offset from the values of the autocorrelation function and changing a sampling frequency using the sampling frequency offset.